Trade Mark Journal No.2018/016 20 April 2018
UK00003301373 4 April 2018 (5)
KAPLYENT
International priority date claimed: 7 November 2017
(United States)
- Class 5
- Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, digital ulcers, and cerebrovascular diseases; vaccines; anxiolytics; anti-allergics; anti-infectives.
Johnson & Johnson
Representative: D Young & Co LLP